SCHEMBL1001937

SCHEMBL1001937

COc1ccc(CNCc2cn(-c3ccc(I)cc3)nc2-c2ccccc2)c(OC)c1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CCNE1 P24864 4/20 0.51
CDK2 P24941 4/20 0.51
ALDH1A1 P00352 11/20 0.50
KDM4E B2RXH2 8/20 0.50
MAPK1 P28482 5/20 0.50
HTT P42858 3/20 0.50
SMN1; SMN2 Q16637 2/20 0.50
HSD17B10 Q99714 2/20 0.50
APLNR P35414 1/20 0.50
OPRM1 P35372 1/20 0.50
OPRD1 P41143 1/20 0.50
RAB9A P51151 1/20 0.50
TSHR P16473 1/20 0.50
NPSR1 Q6W5P4 3/20 0.49
MEN1 O00255 2/20 0.49
KMT2A Q03164 2/20 0.49
MAPT P10636 3/20 0.48
POLB P06746 1/20 0.48
LMNA P02545 3/20 0.47
GAA P10253 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3508065 0.91 ALDH1A1 (0.49) CCNE1CDK2ALDH1A1KDM4EMAPK1
SCHEMBL3508751 0.90 ALDH1A1 (0.59) ALDH1A1KDM4EMAPK1SMN1; SMN2HSD17B10
SCHEMBL8221621 0.89 CCNE1 (0.50) CCNE1CDK2ALDH1A1KDM4EMAPK1
SCHEMBL3507786 0.89 CCNE1 (0.48) CCNE1CDK2ALDH1A1KDM4EMAPK1
SCHEMBL1003021 0.81 APLNR (0.51) ALDH1A1KDM4EAPLNROPRM1OPRD1
SCHEMBL13271695 0.80 ALDH1A1 (0.49) CCNE1CDK2ALDH1A1KDM4EMAPK1
SCHEMBL8233529 0.79 ALDH1A1 (0.59) ALDH1A1KDM4EMAPK1HTTSMN1; SMN2
SCHEMBL8232921 0.78 CCNE1 (0.47) CCNE1CDK2ALDH1A1KDM4EMAPK1
SCHEMBL1004348 0.77 APLNR (0.54) ALDH1A1KDM4EMAPK1SMN1; SMN2APLNR
SCHEMBL1001887 0.75 MAPK1 (0.41) CCNE1CDK2ALDH1A1KDM4EMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8263624-B2 Aryl-substituted heterocycles, and use thereof BAYER INTELLECTUAL PROPERTY GMBH (DE) 2012-09-11 US disclosed
US-8263624-B2 Aryl-substituted heterocycles, and use thereof BAYER INTELLECTUAL PROPERTY GMBH (DE) 2012-09-11 US disclosed
US-8263624-B2 Aryl-substituted heterocycles, and use thereof BAYER INTELLECTUAL PROPERTY GMBH (DE) 2012-09-11 US disclosed
US-20110015241-A1 SUBSTITUTED HETEROCYCLES AND USE THEREOF BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2011-01-20 US disclosed
US-20110015241-A1 SUBSTITUTED HETEROCYCLES AND USE THEREOF BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2011-01-20 US disclosed
US-20110015241-A1 SUBSTITUTED HETEROCYCLES AND USE THEREOF BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2011-01-20 US disclosed
US-20100029651-A1 ARYL-SUBSTITUTED HETEROCYCLES, AND USE THEREOF BAYER HEALTHCARE AG 2010-02-04 US disclosed
US-20100029651-A1 ARYL-SUBSTITUTED HETEROCYCLES, AND USE THEREOF BAYER HEALTHCARE AG 2010-02-04 US disclosed
US-20100029651-A1 ARYL-SUBSTITUTED HETEROCYCLES, AND USE THEREOF BAYER HEALTHCARE AG 2010-02-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110015241-A1 SUBSTITUTED HETEROCYCLES AND USE THEREOF F2, VKORC1, HMBS CCNE1 503/4885CDK2 398/4885ALDH1A1 529/4885
US-20100029651-A1 ARYL-SUBSTITUTED HETEROCYCLES, AND USE THEREOF AHR, CYP2C19, PAH CCNE1 925/4885CDK2 536/4885ALDH1A1 318/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.